CAS NO: | 1051366-32-5 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Balixafortide (POL6326) is a potent, selective, well-tolerated peptidicCXCR4antagonist with anIC50< 10 nM. Balixafortide shows 1000-fold selective forCXCR4than a large panel of receptors includingCXCR7. Balixafortide blocksβ-arrestinrecruitment and calcium flux with IC50s< 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2]. | |
IC50& Target[1] |
| |
体外研究 (In Vitro) | Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Namalwa (IC50< 200 nM) and Jurkat (IC50< 400 nM). Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC50< 20 nM), Namalwa and Jurkat cells (IC50< 10 nM)[1]. | |
体内研究 (In Vivo) | Balixafortide is optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability[1]. | |
Clinical Trial | ||
分子量 | 1864.14 | |
Formula | C84H118N24O21S2 | |
CAS 号 | 1051366-32-5 | |
Sequence | Cyclo(Ala-Cys-Ser-Ala-{D-Pro}-{Dab}-Arg-Tyr-Cys-Tyr-Gln-Lys-{D-Pro}-Pro-Tyr-His) (Disulfide bridge: Cys2-Cys9) | |
Sequence Shortening | Cyclo(ACSA-{D-Pro}-{Dab}-RYCYQK-{D-Pro}-PYH) (Disulfide bridge: Cys2-Cys9) | |
运输条件 | Room temperature in continental US; may vary elsewhere. | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |